Literature DB >> 14662103

New and emerging data from clinical trials of statins.

John C LaRosa1.   

Abstract

Recent clinical trials of statins have clearly demonstrated the benefit of statin therapy in preventing both coronary and cerebral vascular events. These benefits have been demonstrated to be present without reference to older age, sex, or comorbid conditions, including hypertension and diabetes. Future trials will test the value of more aggressive low-density lipoprotein cholesterol lowering, the value of immediate statin intervention during acute coronary syndromes, the role of cholesterol lowering with or without angioplasty, and the role of cholesterol lowering in stroke prevention.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14662103     DOI： 10.1007/s11883-004-0111-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  30 in total

Review 1.  What is the optimal age for starting lipid lowering treatment? A mathematical model.

Authors:  S Ulrich; A D Hingorani; J Martin; P Vallance
Journal:  BMJ       Date:  2000-04-22

Review 2.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

Authors:  P R Hebert; J M Gaziano; K S Chan; C H Hennekens
Journal:  JAMA       Date:  1997 Jul 23-30       Impact factor: 56.272

3.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

4.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Authors: 
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

7.  Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

Authors:  Vasilios G Athyros; Athanasios A Papageorgiou; Bodosakis R Mercouris; Valasia V Athyrou; Athanasios N Symeonidis; Elias O Basayannis; Dimokritos S Demitriadis; Athanasios G Kontopoulos
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580

8.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.

Authors:  Patrick W J C Serruys; Pim de Feyter; Carlos Macaya; Norbert Kokott; Jacques Puel; Matthias Vrolix; Angelo Branzi; Marcelo C Bertolami; Graham Jackson; Bradley Strauss; Bernhard Meier
Journal:  JAMA       Date:  2002-06-26       Impact factor: 56.272

Review 9.  Unresolved issues in early trials of cholesterol lowering.

Authors:  J C LaRosa
Journal:  Am J Cardiol       Date:  1995-09-28       Impact factor: 2.778

10.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.

Authors:  Hallvard Holdaas; Bengt Fellström; Alan G Jardine; Ingar Holme; Gudrun Nyberg; Per Fauchald; Carola Grönhagen-Riska; Søren Madsen; Hans-Hellmut Neumayer; Edward Cole; Bart Maes; Patrice Ambühl; Anders G Olsson; Anders Hartmann; Dag O Solbu; Terje R Pedersen
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321
View more
  1 in total

1.  Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.

Authors:  Zheng Zhou; Elham Rahme; Michal Abrahamowicz; Jack V Tu; Mark J Eisenberg; Karin Humphries; Peter C Austin; Louise Pilote
Journal:  CMAJ       Date:  2005-04-26       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.